Skip to main content
. 2010 Jun 24;3:15–25. doi: 10.2147/ott.s4833

Table 1.

Previous ipilimumab trials

Study (Number of patients) Median survival time (Months)
CA184-008 (N = 155) 10.2, 95% CI (7.6–16.3)
CA184-002 (N = 217) 11.4, 95% CI (6.9–16.1)
With 214 treated; n = 72 at 10 mg/kg Ipilimumab + placebo (n = 57) 19.3, 95% CI (12.0–Not reached)
CA184-007 (N = 115) Ipilimumab + budesonide (n = 58) 17.7, 95% CI (6.8–Not reached)